Eli Lilly & Co.'s new weight-loss pill had lower weight loss and higher rates of nausea and vomiting than anticipated in a study, according to the company. That news sent the stock plunging Thursday morning, even though the company raised its yearly profit and sales outlook. In the study, patients taking the drug orforglipron, lost roughly 11% of their body weight, about 25 pounds. Bloomberg's Damian Garde reports.

See Full Page